Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVT-2163 and MVT-5873 PET Imaging in Pancreatic Cancer
NCT02687230Phase 1Terminated
- Sponsor
- BioNTech SE
- Start
- Jul 2016
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of MVT-2163 in pancreatic ductal adenocarcinoma (PDAC) and malignant neoplasm (3 cohorts), sponsored by BioNTech SE. Primary endpoints: Safety of MVT-2163 alone and in combination with MVT-5873 at 12 months, Peak Plasma Concentration (Cmax) of MVT-2163 alone and in combination with MVT-5873 at 12 months and 5 more. Started Jul 2016; status: terminated.
02
Drugs
MVT-2163
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)malignant neoplasm
Beyond the preview
Go deeper on NCT02687230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687230.